ContraVir Pharmaceuticals Appoints Two New Hepatitis B Experts to Scientific Advisory Board
April 09 2018 - 6:00AM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development and commercialization of
targeted antiviral therapies, announced today the appointment of
leading researchers in hepatitis B virus (HBV) to its Scientific
Advisory Board (SAB). The newly appointed members, Professor Henry
Chan Lik Yuen and Professor Jin-Lin Hou, will add support and
expertise in continued development of the company’s products and
business objectives.
“We are extremely excited about the expansion of our SAB,”
commented James Sapirstein, Chief Executive Officer of ContraVir.
“The 505 (b)(2) Regulatory Pathway news announcement shared
earlier this year, allows us to forge new discussions with other
potential markets. I am confident the advice and guidance of these
renowned experts will prove invaluable advances to the company’s
pipeline, as we continue to position ContraVir as one of the top
leaders in search of an HBV cure.”
Dr. Henry Chan Lik Yuen, MD.
Professor Henry Chan Lik is currently Head of Division of
Gastroenterology and Hepatology, Director of Institute of Digestive
Disease, Director of Center for Liver Health, Director of Office of
Global Engagement, and Assistant Dean (External Affairs) of Faculty
of Medicine at the Chinese University of Hong Kong. A key
investigator in over 25 international trials on antiviral treatment
of chronic hepatitis B and C, Professor Chan today is the global
lead author in publications on peginterferon-alfa,
peginterferon-lambda, telbivudine, and tenofovir for the treatment
of viral hepatitis B with over 350 papers in peer-reviewed
journals. His research work on chronic hepatitis B has helped to
decipher the relationship between the genetics of hepatitis B virus
and disease progression.
Dr. Jin-Lin Hou, MD.
Professor Jin-Lin Hou is the Director and Professor of the
Hepatology Unit and Department of Infectious Diseases, Nanfang
Hospital, Southern Medical University, China. Previously, Professor
Hou served as President of the Chinese Medical Association of
Infectious Diseases, as well as President of APASL 2017. He has
been invited to deliver talks at both national and international
liver conferences owing to his expertise in viral hepatitis. His
current research interests include the clinical management of viral
hepatitis and the molecular virology and immunology of hepatitis B
virus (HBV) and severe acute respiratory syndrome (SARS) infection.
Professor Hou has published more than 400 articles peer-reviewed
journals, including Hepatology, Journal of Hepatology, GUT,
Gastroenterology, NEJM, Lancet Infectious Diseases and Science, et
al.
About ContraVir Pharmaceuticals ContraVir is a
biopharmaceutical company focused on the development and
commercialization of targeted antiviral therapies with a specific
focus on developing a potentially curative therapy for hepatitis B
virus (HBV). The company is developing two novel anti-HBV compounds
with complementary mechanisms of action. TXL™, designed to deliver
high intrahepatic concentrations of TFV while minimizing off-target
effects caused by high levels of circulating TFV (bone and kidney),
recently completed a Phase 2a trial. CRV431, the other anti-HBV
compound, is a next-generation cyclophilin inhibitor with a unique
structure that increases its potency and selective index against
HBV. In vitro and in vivo studies have thus far demonstrated that
CRV431 reduces HBV DNA and other viral proteins, including surface
antigen (HBsAg). For more information
visit www.contravir.com
Forward Looking Statements Certain statements
in this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend,"
among others. These forward-looking statements are based on
ContraVir's current expectations and actual results could differ
materially. There are a number of factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a
going concern; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties with respect to
lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results;
uncertainties of government or third party payer reimbursement;
limited sales and marketing efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any drug
candidates under development, there are significant risks in the
development, regulatory approval, and commercialization of new
products. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or
that any product will receive regulatory approval for any
indication or prove to be commercially successful. ContraVir does
not undertake an obligation to update or revise any forward-looking
statement. Investors should read the risk factors set forth in
ContraVir's Form 10-KT for the year ended December 30, 2017 and
other periodic reports filed with the Securities and Exchange
Commission.
For further information, please contact: Sharen
Pyatetskaya Director of Investor Relationssp@contravir.com; (732)
902-4028
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Sep 2023 to Sep 2024